TCX-102 / BlueSphere Bio - LARVOL DELTA

BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients (GlobeNewswire) - "...BlueSphere also announced three additional blood-restricted miHA TCR product candidates that are ready for clinical development - all discovered utilizing the TCXpress platform. Together, these four TCR T-cell therapy candidates comprising the TCX-101 program positions the Company’s miHA portfolio with best-in-class HLA coverage in these hematologic indications....To further expand the reach of our TCR-based portfolio, BlueSphere has broadened its pipeline to address an additional subset of AML patients having mutated NPM1. Utilizing TCXpress, the Company identified and subsequently nominated a single lead TCR reactive against mutant NPM-1 for the TCX-102 program....IND enabling work is underway with an IND filing anticipated in 2Q2025."

IND • New molecule • Acute Myelogenous Leukemia